Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AgenusAGEN +4.40%43 EV-to-EBIT is 2.33 as of Aug. 18, 2026. GuruFocus rates AGEN with a GF Score™ of 43/100 and a GF Value™ of $3.78 (Significantly Overvalued). The stock has 12 warning signs investors should review. Among 370 Biotechnology companies, Agenus ranks better than 73.24% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Agenus's Enterprise Value is $351.4 Mil.
Agenus's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $151.0 Mil. Therefore, Agenus's EV-to-EBIT for today is 2.33.
The historical rank and industry rank for Agenus's EV-to-EBIT or its related term are showing as below:
AGEN'
s EV-to-EBIT Range Over the Past 10 Years
Min: -8.58 Med: -2.48 Max: 17.62
Current: 2.33
During the past 13 years, the highest EV-to-EBIT of Agenus was 17.62. The lowest was -8.58. And the median was -2.48.
AGEN's EV-to-EBIT is ranked better than 73.24% of 370
companies
in the Biotechnology industry
Industry Median: 16.115
vs AGEN: 2.33
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Agenus's Enterprise Value for the quarter that ended in Jun. 2026 was $152.1 Mil.
Agenus's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $151.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agenus EV-to-EBIT Related Terms
Agenus EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Agenus's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Agenus's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agenus EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Agenus's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Agenus's EV-to-EBIT falls into.
Agenus's current Enterprise Value is $351.4 Mil.
Agenus's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $151.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agenus (AGEN) has a EV-to-EBIT of 2.33 as of Aug. 18, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Agenus and its competitors. According to the industry distribution chart, Agenus ranks #99 out of 370 companies in the Biotechnology industry, placing it in the top 26.8%.
Is Agenus' EV-to-EBIT too high?
Agenus' current EV-to-EBIT is 2.33. The Biotechnology industry median EV-to-EBIT is 16.12. Agenus' value of 2.33 is 85.5% below this industry median. Based on the distribution chart, Agenus ranks #99 out of 370 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Agenus has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Agenus' EV-to-EBIT compare to FULC and IRD?
According to the Biotechnology industry distribution chart, Agenus ranks #99 out of 370 companies for EV-to-EBIT. This puts Agenus in the upper half of its industry. The industry median EV-to-EBIT is 16.12. Agenus' value of 2.33 is 85.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.12, based on 370 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Agenus's current EV-to-EBIT of 2.33 is 85.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Agenus and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agenus's current EV-to-EBIT is 2.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agenus stock overvalued right now?
Based on GuruFocus' analysis, Agenus (AGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.78, compared to a current price of $7.47 — trading 97.6% above its estimated fair value. The current EV-to-EBIT is 2.33 and 85.5% below the Biotechnology industry median of 16.12. Agenus' overall GF Score™ is 43/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Agenus (AGEN), the current EV-to-EBIT is 2.33 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agenus (AGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Agenus stock appears to be overvalued.
The current stock price of $7.47 is trading 97.6% above its estimated GF Value™ of $3.78.
GuruFocus considers Agenus to be Significantly Overvalued.
Key valuation signals for AGEN:
EV-to-EBIT: 2.33
GF Value™: $3.78 vs. price of $7.47 (97.6% above fair value)
Industry Position: 85.5% below the Biotechnology median (#99 of 370)
No single metric tells the full story. See the AGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
43GF Score
Get the complete analysis for AGEN
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AGEN has been successfully added to your 
